ClinicalTrials.gg
CompletedNCT02603809Updated Nov 23, 2022Results posted

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

A Phase 2 interventional study of Aprocitentan 5 mg and Aprocitentan 10 mg in Essential Hypertension, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 91 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-23.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,659
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Essential Hypertension with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. Essential Hypertension · United States.

Enrollment
Largest of 46
1,659 · median 275
Started
2015
with 3 others
Phase 2
5 of 53
none open now
Registered
29th of 53
by date

Among the 53 studies in Essential Hypertension with a site in United States, this one has the largest enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2015, is one of 5 in phase 2, and was the 29th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

8 of the 53 studies in Essential Hypertension with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Essential Hypertension with a site in United States, or all of them as a file.
02

Study summary

The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.

Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral regimen of 4 doses of ACT-132577.

Read the detailed description

Participation in the study is planned to last up to 18 weeks. A single-blind placebo run-in period of 4 to 6 weeks after which participants will be randomized into a double-blind treatment period of 8 weeks and a washout and follow-up period ending with an end-of-study visit approximately 12 weeks after randomization.

03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure
  • No to stop (according to label) anti-hypertensive treatment(s) at screening
  • Mild-to-moderate essential hypertension with or without ongoing anti-hypertensive treatment(s):

    -- Mean (of 5 measurements) sitting diastolic blood pressure (SiDBP) ≥ 90 to \< 110 mmHg measured by office blood pressure measurements (OBPM).

  • Women of must have a negative pregnancy test and use of reliable methods of

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension (grade 3): mean sitting systolic/diastolic BP (SiSBP/SiDBP; measured by OBPM) ≥ 180/110 mmHg, respectively.
  • Secondary hypertension
  • Known hypertensive retinopathy greater than Keith-Wagener Grade 2
  • Myocardial infarction, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within 12 months prior to randomization
  • Unstable angina within 6 months prior to randomization
  • Heart failure class III and IV
  • Valvular defects (such as severe aortic or mitral valve disease) and/or hemodynamically relevant rhythm disturbances
  • Clinical evidence of cerebrovascular insufficiency or a cerebrovascular accident within 6 months prior to randomization.
  • Subjects working night shifts
  • \< 20 kg/m2 or > 40 kg/m2
  • Treatment with any medication which may affect BP (e.g., treatment of psychiatric diseases, ophthalmic preparations)
  • Treatment with strong cytochrome P450 3A4 () isoenzyme inhibitors or inducers
  • Treatment with guanethidine and/or mineralocorticoid receptor antagonists within 1 month prior to Screening (Visit 1)
  • Treatment with another treatment within 1 month prior to Screening (Visit 1)
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,659 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.

    Drug: Placebo

  • Experimental
    Aprocitentan 5 mg

    After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.

    Drug: Aprocitentan 5 mg

  • Experimental
    Aprocitentan 10 mg

    After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.

    Drug: Aprocitentan 10 mg

  • Experimental
    Aprocitentan 25 mg

    After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.

    Drug: Aprocitentan 25 mg

  • Experimental
    Aprocitentan 50 mg

    After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.

    Drug: Aprocitentan 50 mg

  • Active comparator
    Lisinopril 20 mg

    After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.

    Drug: Lisinopril 20 mg

Interventions

  • One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.

    Also known as: ACT-132577

  • Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.

    Also known as: ACT-132577

  • One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.

    Also known as: ACT-132577

  • One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.

    Also known as: ACT-132577

  • One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan

  • DrugPlacebo

    One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough

    Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The absolute change in mean trough sitting diastolic blood pressure (SiDBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the diastolic blood pressure from the start of treatment.

    Time frame: Baseline (Day 1) and end of double-blind treatment (Day 56)

Secondary outcomes

  1. Change From Baseline to End of Double-blind Treatment in Sitting Systolic Blood Pressure at Trough

    Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The absolute change in mean trough sitting systolic blood pressure (SiSBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the systolic blood pressure from the start of treatment.

    Time frame: Baseline (Day 1) and end of double-blind treatment (Day 56)

  2. Control Rates at the End of the Double-blind Treatment Period Based on Trough Sitting Diastolic and Systolic Blood Pressure

    Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The Canadian Hypertension Education Program (CHEP) issued guidelines proposing cut-offs of 85 mmHg for diastolic blood pressure and 135 mmHg for systolic blood pressure specifically focusing on measurement by automated office blood pressure measurement. The number of participants at the end of the 8-week treatment period that had values below the protocol and CHEP cut-off values are reported. The initial protocol control rates at Week 8 (Day 56) on trough SiDBP are also reported and were defined as a SiDBP of less than 90 mmHg and a SiSBP of less than 140 mmHg.

    Time frame: End of double-blind treatment (Day 56)

  3. Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Diastolic Blood Pressure

    Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. A participant was a responder if the reduction from baseline in mean trough sitting diastolic blood pressure (SiDBP) was 10 mmHg or greater-than 10 mmHg.

    Time frame: Baseline (Day 1) and end of double-blind treatment (Day 56)

  4. Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Systolic Blood Pressure

    Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. A participant was a responder if the reduction from baseline in mean trough sitting systolic blood pressure (SiSBP) was 20 mmHg or greater-than 20 mmHg.

    Time frame: Baseline (Day 1) and end of double-blind treatment (Day 56)

  5. Change From Baseline to End of Double-blind Treatment in 24-hour Diastolic and Systolic Ambulatory Blood Pressure Monitoring (ABPM)

    Diastolic and systolic ambulatory blood pressure monitoring was performed over a 24-hour period with the ABPM device (Mobil-o-Graph) set to record diastolic and systolic blood pressure at a pre-defined time. Over a 24-hour period 3 measurements per hour during the day and 2 per hour during the night were made. The blood pressure measurements were derived from the area under the diastolic and systolic blood pressure curves and divided by the time span and averaged. For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.

    Time frame: Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)

  6. Ratio of Group Mean at Trough to Group Mean at Peak for Diastolic Blood Pressure Based on Ambulatory Blood Pressure Monitoring (ABPM)

    Ratio of group mean at trough to group mean at peak was calculated from the diastolic ambulatory blood pressure monitoring performed over a 24-hour period with the ABPM device. The trough (the smallest blood pressure reduction) and the peak (the highest blood pressure reduction) ratio show the extent of blood pressure lowering throughout the 24-hour dosing interval in the group. The group mean trough (at 20-24 hours) to group mean (at 2-6 hours) peak of diastolic blood pressure were examined to evaluate the extent to which once-daily dosing criteria were met (trough-to-peak values greater than 0.5). The ratio is positive if there was a decrease in diastolic blood pressure at both the trough and peak times at the end of treatment (Day 55 to Day 56) when compared to baseline (Day -1 to Day 1). For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.

    Time frame: Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)

Other outcomes

  1. Supportive Analysis of Primary Endpoint: Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough

    Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The absolute change in mean trough sitting diastolic blood pressure (SiDBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the diastolic blood pressure from the start of treatment.

    Time frame: Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)

07

Results

Posted Apr 13, 2020

Participant flow

The study was conducted at 99 sites in 3 countries. Of the 1659 participants that signed the informed consent 996 entered the run-in period (i.e. 663 participants were screening failures: 651 failed to meet the eligibility criteria to enter the run-in period, 6 withdrew and 6 did not enter the run-in period for other reasons).

Participant flow — Overall Study
MilestonePlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mg
Started828282828181
Per-protocol set676871676869
Modified per-protocol set666871676869
Completed study757979767875
Completed707475707071
Not completed1287121110
Withdrew: Withdrawal by subject412334
Withdrew: Lost to follow-up231422
Withdrew: Pre-specified discontinuation criteria332231
Withdrew: Physician decision000121
Withdrew: Adverse event302211
Withdrew: Lack of efficacy010001

Outcome measures

PrimaryChange From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough

Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The absolute change in mean trough sitting diastolic blood pressure (SiDBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the diastolic blood pressure from the start of treatment.

Time frame:
Baseline (Day 1) and end of double-blind treatment (Day 56)
Reported as:
Mean · mmHg
Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough
mmHgPlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mg
Baseline97.5 ± 5.497.8 ± 5.597.7 ± 4.397.8 ± 4.898.2 ± 5.396.8 ± 4.6
Absolute Change from Baseline to Week 8-4.9 ± 11.1-6.3 ± 8.9-9.9 ± 8.7-12.0 ± 8.2-10.0 ± 7.9-8.4 ± 9.6
Statistical analysis
  • Placebo vs Aprocitentan 5 mg vs Aprocitentan 10 mg vs Aprocitentan 25 mg vs Aprocitentan 50 mg · Multiple Comparison Procedure-Modeling · p = <0.001
  • Placebo vs Aprocitentan 5 mg · ANCOVA · p = 0.8117 · Ls mean: -1.31 · 95% CI -5.10 to 2.49with Dunnett correction.
  • Placebo vs Aprocitentan 10 mg · ANCOVA · p = 0.0053 · Ls mean: -4.93 · 95% CI -8.68 to -1.17with Dunnett correction.
  • Placebo vs Aprocitentan 25 mg · ANCOVA · p = <.0001 · Ls mean: -6.99 · 95% CI -10.80 to -3.19with Dunnett correction.
  • Placebo vs Aprocitentan 50 mg · ANCOVA · p = 0.0057 · Ls mean: -4.95 · 95% CI -8.75 to -1.15with Dunnett correction.
SecondaryChange From Baseline to End of Double-blind Treatment in Sitting Systolic Blood Pressure at Trough

Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The absolute change in mean trough sitting systolic blood pressure (SiSBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the systolic blood pressure from the start of treatment.

Time frame:
Baseline (Day 1) and end of double-blind treatment (Day 56)
Reported as:
Mean · mmHg
Change From Baseline to End of Double-blind Treatment in Sitting Systolic Blood Pressure at Trough
mmHgPlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mg
Baseline149.2 ± 13.1149.4 ± 13.9149.8 ± 12.7151.2 ± 13.7148.6 ± 12.8149.8 ± 14.2
Absolute Change from Baseline to Week 8-7.7 ± 18.8-10.3 ± 15.3-15.0 ± 14.5-18.5 ± 15.0-15.1 ± 11.8-12.8 ± 16.0
Statistical analysis
  • Placebo vs Aprocitentan 5 mg vs Aprocitentan 10 mg vs Aprocitentan 25 mg vs Aprocitentan 50 mg · Multiple Comparison Procedure-Modeling · p = <0.001
  • Placebo vs Aprocitentan 5 mg · ANCOVA · p = 0.7071 · Ls mean: -2.45 · 95% CI -8.44 to 3.54with Dunnett correction.
  • Placebo vs Aprocitentan 10 mg · ANCOVA · p = 0.0138 · Ls mean: -7.05 · 95% CI -12.98 to -1.12with Dunnett correction.
  • Placebo vs Aprocitentan 25 mg · ANCOVA · p = 0.0003 · Ls mean: -9.90 · 95% CI -15.92 to -3.88with Dunnett correction.
  • Placebo vs Aprocitentan 50 mg · ANCOVA · p = 0.0077 · Ls mean: -7.58 · 95% CI -13.58 to -1.59with Dunnett correction.
SecondaryControl Rates at the End of the Double-blind Treatment Period Based on Trough Sitting Diastolic and Systolic Blood Pressure

Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The Canadian Hypertension Education Program (CHEP) issued guidelines proposing cut-offs of 85 mmHg for diastolic blood pressure and 135 mmHg for systolic blood pressure specifically focusing on measurement by automated office blood pressure measurement. The number of participants at the end of the 8-week treatment period that had values below the protocol and CHEP cut-off values are reported. The initial protocol control rates at Week 8 (Day 56) on trough SiDBP are also reported and were defined as a SiDBP of less than 90 mmHg and a SiSBP of less than 140 mmHg.

Time frame:
End of double-blind treatment (Day 56)
Reported as:
Count of participants · Participants
Control Rates at the End of the Double-blind Treatment Period Based on Trough Sitting Diastolic and Systolic Blood Pressure
ParticipantsPlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mg
SiDBP less than 90 mmHg223037433938
SiDBP less than 85 mmHg (CHEP)171529292123
SiSBP less than 140 mmHg343743444739
SiSBP less than 135 mmHg (CHEP)242732383631
SecondaryResponse Rates at End of Double-blind Treatment Period Based on Trough Sitting Diastolic Blood Pressure

Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. A participant was a responder if the reduction from baseline in mean trough sitting diastolic blood pressure (SiDBP) was 10 mmHg or greater-than 10 mmHg.

Time frame:
Baseline (Day 1) and end of double-blind treatment (Day 56)
Reported as:
Count of participants · Participants
Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Diastolic Blood Pressure
ParticipantsPlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mg
Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Diastolic Blood Pressure212134403831
SecondaryResponse Rates at End of Double-blind Treatment Period Based on Trough Sitting Systolic Blood Pressure

Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. A participant was a responder if the reduction from baseline in mean trough sitting systolic blood pressure (SiSBP) was 20 mmHg or greater-than 20 mmHg.

Time frame:
Baseline (Day 1) and end of double-blind treatment (Day 56)
Reported as:
Count of participants · Participants
Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Systolic Blood Pressure
ParticipantsPlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mg
Response Rates at End of Double-blind Treatment Period Based on Trough Sitting Systolic Blood Pressure161622282220
SecondaryChange From Baseline to End of Double-blind Treatment in 24-hour Diastolic and Systolic Ambulatory Blood Pressure Monitoring (ABPM)

Diastolic and systolic ambulatory blood pressure monitoring was performed over a 24-hour period with the ABPM device (Mobil-o-Graph) set to record diastolic and systolic blood pressure at a pre-defined time. Over a 24-hour period 3 measurements per hour during the day and 2 per hour during the night were made. The blood pressure measurements were derived from the area under the diastolic and systolic blood pressure curves and divided by the time span and averaged. For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.

Time frame:
Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)
Reported as:
Mean · mmHg
Change From Baseline to End of Double-blind Treatment in 24-hour Diastolic and Systolic Ambulatory Blood Pressure Monitoring (ABPM)
mmHgPlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mg
Baseline 24-hour mean DBP90.46 ± 10.6690.60 ± 10.1992.60 ± 10.9289.28 ± 9.5391.53 ± 10.5491.18 ± 9.48
Absolute change in 24-hour mean DBP at Week 8-2.49 ± 5.52-3.76 ± 6.36-6.55 ± 7.04-8.86 ± 7.35-5.98 ± 6.63-5.72 ± 9.12
Baseline 24-hour mean SBP140.28 ± 14.2139.90 ± 15.87144.30 ± 15.68140.83 ± 11.23141.28 ± 14.73143.35 ± 17.53
Absolute change in 24-hour mean SBP at Week 8-3.54 ± 7.46-3.16 ± 10.54-7.72 ± 11.37-9.23 ± 9.92-6.07 ± 8.93-7.23 ± 14.33
SecondaryRatio of Group Mean at Trough to Group Mean at Peak for Diastolic Blood Pressure Based on Ambulatory Blood Pressure Monitoring (ABPM)

Ratio of group mean at trough to group mean at peak was calculated from the diastolic ambulatory blood pressure monitoring performed over a 24-hour period with the ABPM device. The trough (the smallest blood pressure reduction) and the peak (the highest blood pressure reduction) ratio show the extent of blood pressure lowering throughout the 24-hour dosing interval in the group. The group mean trough (at 20-24 hours) to group mean (at 2-6 hours) peak of diastolic blood pressure were examined to evaluate the extent to which once-daily dosing criteria were met (trough-to-peak values greater than 0.5). The ratio is positive if there was a decrease in diastolic blood pressure at both the trough and peak times at the end of treatment (Day 55 to Day 56) when compared to baseline (Day -1 to Day 1). For ambulatory blood pressure monitoring the baseline was the period from the time of last run-in placebo intake up to the time of the first double-blind treatment intake.

Time frame:
Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)
Reported as:
Number · Ratio of mean at trough to mean at peak
Ratio of Group Mean at Trough to Group Mean at Peak for Diastolic Blood Pressure Based on Ambulatory Blood Pressure Monitoring (ABPM)
Ratio of mean at trough to mean at peakPlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mg
Ratio of Group Mean at Trough to Group Mean at Peak for Diastolic Blood Pressure Based on Ambulatory Blood Pressure Monitoring (ABPM)-48.032.590.901.491.250.65
Other pre-specifiedSupportive Analysis of Primary Endpoint: Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough

Participants had their blood pressure measured at the study site using the BpTRU® device. The BpTRU® is an automatic unattended office blood pressure measurement device. Six measurements, at rest, per participant per visit were performed. The mean of the last 5 measurements was used for the analysis. The absolute change in mean trough sitting diastolic blood pressure (SiDBP) measured by from baseline (i.e., at randomization) to week 8 (Day 56). A negative change indicates a decrease in the diastolic blood pressure from the start of treatment.

Time frame:
Baseline (Day -1 to Day 1) and end of double-blind treatment (Day 55 and Day 56)
Reported as:
Mean · mmHg
Supportive Analysis of Primary Endpoint: Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough
mmHgPlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mg
Baseline98.0 ± 5.597.5 ± 5.397.7 ± 4.298.2 ± 5.098.4 ± 5.396.9 ± 4.4
Absolute Change from Baseline to Week 8-4.2 ± 11.1-5.8 ± 8.9-9.9 ± 8.4-11.7 ± 7.8-9.9 ± 7.8-8.2 ± 9.7
Statistical analysis
  • Placebo vs Aprocitentan 5 mg vs Aprocitentan 10 mg vs Aprocitentan 25 mg vs Aprocitentan 50 mg · Multiple Comparison Procedure-Modeling · p = <0.001
  • Placebo vs Aprocitentan 5 mg · ANCOVA · p = 0.5356 · Ls mean: -1.75 · 95% CI -5.19 to 1.69with Dunnett correction.
  • Placebo vs Aprocitentan 10 mg · ANCOVA · p = 0.0001 · Ls mean: -5.82 · 95% CI -9.25 to -2.40with Dunnett correction.
  • Placebo vs Aprocitentan 25 mg · ANCOVA · p = <.0001 · Ls mean: -7.50 · 95% CI -10.96 to -4.04with Dunnett correction.
  • Placebo vs Aprocitentan 50 mg · ANCOVA · p = 0.0003 · Ls mean: -5.65 · 95% CI -9.11 to -2.19with Dunnett correction.

Adverse events

Collected over Up to 12 weeks after first intake of medication after randomization.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/82 (0%)0/82 (0%)30/82 (36.6%)
Aprocitentan 5 mg0/82 (0%)0/82 (0%)18/82 (22%)
Aprocitentan 10 mg0/82 (0%)0/82 (0%)24/82 (29.3%)
Aprocitentan 25 mg0/82 (0%)2/82 (2.4%)32/82 (39%)
Aprocitentan 50 mg0/81 (0%)0/81 (0%)22/81 (27.2%)
Lisinopril 20 mg0/81 (0%)1/81 (1.2%)25/81 (30.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mg
FallInjury, poisoning and procedural complications0/820/820/820/820/811/81
Jaw fractureInjury, poisoning and procedural complications0/820/820/820/820/811/81
Bundle branch block leftCardiac disorders0/820/820/821/820/810/81
Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/820/820/821/820/810/81
Most frequent other events
Showing 10 of 152
Most frequent other events
EventPlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mg
NasopharyngitisInfections and infestations1/821/822/822/820/814/81
HeadacheNervous system disorders1/821/822/822/822/814/81
Upper respiratory tract infectionInfections and infestations1/820/824/821/822/811/81
HypertensionVascular disorders4/821/820/822/823/813/81
ArthralgiaMusculoskeletal and connective tissue disorders2/820/821/821/823/810/81
ConstipationGastrointestinal disorders0/820/823/820/821/810/81
Blood pressure increasedInvestigations3/820/820/820/820/810/81
Oedema peripheralGeneral disorders0/820/820/822/822/810/81
Pain in extremityMusculoskeletal and connective tissue disorders1/821/820/821/822/810/81
Erectile dysfunctionReproductive system and breast disorders0/820/820/820/820/812/81

Baseline characteristics

Full Analysis Set (N=490), i.e. all participants randomized.

Age, Continuous
Age, Continuous(years)PlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mgTotal
Full Analysis Set53.5 ± 9.154.1 ± 8.555.3 ± 9.855.1 ± 10.054.2 ± 9.356.0 ± 9.054.7 ± 9.3
Per Protocol Set53.9 ± 9.155.0 ± 8.555.8 ± 9.555.7 ± 9.854.0 ± 9.456.1 ± 9.455.1 ± 9.3
modified Per Protocol Set54.0 ± 9.155.0 ± 8.555.8 ± 9.555.7 ± 9.854.0 ± 9.456.1 ± 9.455.1 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mgTotal
Full Analysis Set — Female273431372836193
Full Analysis Set — Male554851455345297
Per Protocol Set — Female222726302431160
Per Protocol Set — Male454145374438250
modified Per Protocol Set — Female222726302431160
modified Per Protocol Set — Male444145374438249
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mgTotal
Full Analysis Set — Hispanic or Latino232631272826161
Full Analysis Set — Not Hispanic or Latino595651555355329
Full Analysis Set — Unknown or Not Reported0000000
Per Protocol Set — Hispanic or Latino192228242523141
Per Protocol Set — Not Hispanic or Latino484643434346269
Per Protocol Set — Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mgTotal
Full Analysis Set — American Indian or Alaska Native1021004
Full Analysis Set — Asian2010025
Full Analysis Set — Native Hawaiian or Other Pacific Islander0000011
Full Analysis Set — Black or African American312826352632178
Full Analysis Set — White485453465546302
Full Analysis Set — More than one race0000000
Full Analysis Set — Unknown or Not Reported0000000
Per Protocol Set — American Indian or Alaska Native0021003
Per Protocol Set — Asian1010013
Per Protocol Set — Native Hawaiian or Other Pacific Islander0000011
Per Protocol Set — Black or African American262219262126140
Per Protocol Set — White404649404741263
Per Protocol Set — More than one race0000000
Per Protocol Set — Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)PlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mgTotal
Canada31642521
United States757574737571443
Israel46254526
Weight
Weight(kilograms)PlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mgTotal
Full Analysis Set92.0 ± 18.988.6 ± 16.990.1 ± 18.391.1 ± 16.987.6 ± 15.887.0 ± 17.289.4 ± 17.37
Per Protocol Set91.0 ± 19.288.3 ± 17.689.3 ± 19.091.7 ± 18.187.1 ± 15.886.5 ± 16.089.0 ± 17.7
modified Per Protocol Set90.6 ± 19.088.3 ± 17.689.3 ± 19.091.7 ± 18.187.1 ± 15.886.5 ± 16.089.0 ± 17.7
Body Mass Index
Body Mass Index(kilograms per square meter)PlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mgTotal
Full Analysis Set30.6 ± 5.0730.1 ± 4.5630.8 ± 4.5231.0 ± 4.1630.2 ± 4.5530.4 ± 4.5930.5 ± 4.57
Per Protocol Set30.1 ± 5.129.8 ± 4.530.4 ± 4.631.0 ± 4.330.3 ± 4.730.4 ± 4.630.3 ± 4.6
modified Per Protocol Set30.1 ± 5.129.8 ± 4.530.4 ± 4.631.0 ± 4.330.3 ± 4.730.4 ± 4.630.3 ± 4.6
Duration of essential hypertension at screening
Duration of essential hypertension at screening(years)PlaceboAprocitentan 5 mgAprocitentan 10 mgAprocitentan 25 mgAprocitentan 50 mgLisinopril 20 mgTotal
Full Analysis Set9.13 ± 8.728.12 ± 8.2510.48 ± 10.189.56 ± 8.9710.60 ± 9.9511.79 ± 10.479.94 ± 9.48
Per Protocol Set9.24 ± 8.938.38 ± 8.6210.6 ± 10.519.19 ± 8.6110.35 ± 10.0712.53 ± 10.8810.06 ± 9.7

1 further baseline measures are reported on the registry.

08

Study locations

91 sites
  • Appalachian Cardiovascular Associates
    Fort Payne, Alabama 35967, United States
  • Radiant Research Inc
    Chandler, Arizona 85224, United States
  • Warner Family Practice / Radiant Research Inc
    Chandler, Arizona 85224, United States
  • Phoenix Medical Research Institute LLC
    Peoria, Arizona 85381, United States
  • Advanced Arizona Clinical Research
    Tucson, Arizona 85704, United States
  • Noble Clinical Research LLC
    Tucson, Arizona 85704, United States
  • Desert Sun Clinical Research LLc
    Tucson, Arizona 85710, United States
  • Advanced Research Center Inc
    Anaheim, California 92805, United States
  • Med Center
    Carmichael, California 95608, United States
  • John Muir Physician Network Clinical Research Center
    Concord, California 94520, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Long Beach Center for Clinical Research
    Long Beach, California 90807, United States
  • Entertainment Medical Group Inc
    Los Angeles, California 90036, United States
  • Artemis institute for Clinical Research
    San Diego, California 92103, United States
  • Memorial Research Medical Clinic / Orange County Research Center
    Tustin, California 92780, United States
  • Empire Clinical Research
    Upland, California 91786, United States
  • Clinical Research Consulting LLC
    Milford, Connecticut 06460, United States
  • Chase Medical Research LLC
    Waterbury, Connecticut 06708, United States
  • Alfieri Cardiology
    Wilmington, Delaware 19803, United States
  • ACRC - Cardiology
    Atlantis, Florida 33462, United States
  • Innovative Research of West Florida INC
    Clearwater, Florida 33756, United States
  • Avail Clinical Research LLC
    DeLand, Florida 32720, United States
  • Alan Graff, MD, PA
    Fort Lauderdale, Florida 33308, United States
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • AGA Clinical Trials
    Hialeah, Florida 33012, United States
  • Canvas Clinical Research, LLC
    Lake Worth, Florida 33467, United States
  • LCC Medical Research Institute
    Miami, Florida 33126, United States
  • Allied Biomedical Research Institute, INC
    Miami, Florida 33155, United States
  • Southeast Regional Research Group
    Savannah, Georgia 31401, United States
  • Community Clin Res CTR
    Anderson, Indiana 46011, United States
  • Midwest Institute for Clinical Research
    Indianapolis, Indiana 46260, United States
  • Heartland Research Associated LLC
    Newton, Kansas 67114, United States
  • Heartland Research Associates LLC
    Wichita, Kansas 67205, United States
  • Heartland Research Associates LLC
    Wichita, Kansas 67207, United States
  • Avant Research Associates, LLC
    Crowley, Louisiana 70526, United States
  • Best Clinical Trials LLC
    New Orleans, Louisiana 70115, United States
  • New Orleans Center for Clinical Research - Nola
    New Orleans, Louisiana 70119, United States
  • Clinsite LLC
    Ann Arbor, Michigan 48106, United States
  • Primecare Research Associates, LLC
    Florissant, Missouri 63031, United States
  • Clinical Research Advantage, Inc. / Diagnostic Center Of Medicine - Durango
    Las Vegas, Nevada 89117, United States
  • Premier Research
    Trenton, New Jersey 08611, United States
  • Rochester Clinical Research Inc.
    Rochester, New York 14609, United States
  • Metrolina Internal Medicine/Internal Medicine Research
    Charlotte, North Carolina 28204, United States
  • Pharmquest LLC
    Greensboro, North Carolina 27408, United States
  • Peters Medical Research
    High Point, North Carolina 27262, United States
  • Wake Research Associates
    Raleigh, North Carolina 27604-1547, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58103, United States
  • Sterling Research Group Ltd.
    Cincinnati, Ohio 45219, United States
  • Aventiv Research Inc.
    Columbus, Ohio 43213, United States
  • Dayton Clinical Research
    Dayton, Ohio 45406, United States
  • Aventiv Research Inc.
    Dublin, Ohio 43016, United States
  • Oklahoma City Clinic - Edmond / Radiant Research Inc
    Edmond, Oklahoma 73034, United States
  • Clinical Research Advantage, Inc. / Oklahoma City Clinic - Midwest City
    Midwest City, Oklahoma 73110, United States
  • Willamette Valley Clinical Studies
    Eugene, Oregon 97404, United States
  • Detweiler Family Medicine and Associates PC
    Lansdale, Pennsylvania 19446, United States
  • Suburban Research Center
    Media, Pennsylvania 19063, United States
  • Degarmo Institute of Medical Research
    Greer, South Carolina 29651, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Tekton Research Inc
    Austin, Texas 78745, United States
  • Texas Diabetes & Endocrinology
    Austin, Texas 78749, United States
  • Trinity Hypertension & Metabolic Research Institute
    Carrollton, Texas 75006, United States
  • Family Medicine Associates of Texas - ACRC Trials
    Carrollton, Texas 75010, United States
  • Coastal Bend Clinical Research
    Corpus Christi, Texas 78413, United States
  • TR - Global Medical Research
    DeSoto, Texas 75115, United States
  • Ventavia Research Group, LLC
    Fort Worth, Texas 76104, United States
  • Clinical Investigations of Texas
    Plano, Texas 75075, United States
  • Avant Research Associates LLC
    Port Arthur, Texas 77640, United States
  • Texas Diabetes & Endocrinology
    Round Rock, Texas 78681, United States
  • Radiant Research Inc
    San Antonio, Texas 78229, United States
  • Bandera Family Health Care
    San Antonio, Texas 78249, United States
  • Wasatch Clinical Research LLC
    Salt Lake City, Utah 84107, United States
  • Health Research of Hampton Roads
    Newport News, Virginia 23606, United States
  • National Clinical Research Inc
    Richmond, Virginia 23294, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Manna Research - Vancouver
    Vancouver, British Columbia V6J 1S3, Canada
  • Canadian Phase Onwards Inc
    Toronto, Ontario M3J 2C5, Canada
  • Manna Research - Toronto
    Toronto, Ontario M9W 4L6, Canada
  • Manna Research - Levis
    Levis, Quebec G6W 0M6, Canada
  • Diex Recherche Montreal Inc
    Montreal, Quebec H2Y 1S1, Canada
  • Diex Recherche Montreal Inc
    Montréal, Quebec H2Y 1S1, Canada
  • Manna Research - Pointe Claire
    Pointe-Claire, Quebec H9R 4S3, Canada
  • Diex Reserach Sherbrooke Inc
    Sherbrooke, Quebec J1H 1Z1, Canada
  • Cardiology Department Barzilai
    Ashkelon, 78278, Israel
  • Soroka University Hospital - Hypertension Unit
    Beer Sheva, 84101, Israel
  • The Hyper Unit, Edith Wolfson Medical Center
    Holon, 58100, Israel
  • Hypertension Treatment Center, Internal Dep, Hadassah
    Jerusalem, 91240, Israel
  • Hypertension And Nephrology Department, Meir Medical Center
    Kefar Sava, 44261, Israel
  • Clinical Research Unit Kaplan Medical Center
    Rehovot, 76100, Israel
  • Internal Med Department A, Ziv Medical Center
    Safed, 13100, Israel
  • Advanced Medical Concepts, PSC
    Cidra, 00739, Puerto Rico
  • Research & Cardiovascular Corp.
    Ponce, 00717, Puerto Rico
09

References and documents

Publications

  • Verweij P, Danaietash P, Flamion B, Menard J, Bellet M. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension. Hypertension. 2020 Apr;75(4):956-965. doi: 10.1161/HYPERTENSIONAHA.119.14504. Epub 2020 Feb 17. PubMed 32063059 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Feb 2017, 14 months.

Results were first posted in Apr 2020, 3 years 1 month after primary completion. A results delay was requested in Mar 2018.

Of 16 phase 2 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2015
First posted
Nov 13, 2015
StartActual
Dec 14, 2015
Primary completionActual
Feb 28, 2017
CompletionActual
Apr 7, 2017
Results delay requested
Mar 26, 2018
Results first posted
Apr 13, 2020
Last update
Nov 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02603809
Responsible party
Sponsor
First posted
Nov 13, 2015
Start date
Dec 14, 2015
Primary completion
Feb 28, 2017
Completion
Apr 7, 2017
Results posted
Apr 13, 2020
Last update
Nov 23, 2022

Study contacts

ClinicalTrials
study director · Idorsia Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprocitentan

Start the discussion